Real-World Evidence: Considerations Regarding Non-Interventional Studies for Drug and Biological Products
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
March 21, 2024
April 8, 2024
48325e39-b445-4a53-8cc0-7483dcf3e352
Related Documents
Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products: Draft Guidance for Industry
Guidance DocumentJanuary 9, 2026Center for Drug Evaluation and Research
Regulatory Considerations for Prescription Drug Use-Related Software
Guidance DocumentSeptember 19, 2023Center for Drug Evaluation and Research
Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products
Guidance DocumentFebruary 1, 2023Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox